MHRA approves Dawnzera for hereditary angioedema
Many people will not know the name donidalorsen, but the decision matters. On 7 May 2026, the Medicines and Healthcare products Regulatory Agency approved Dawnzera, the brand name for donidalorsen, for patients aged 12 and over with hereditary angioedema. According to the MHRA, it is intended to help prevent angioedema attacks rather than respond only after an attack has already started.\n\nThat may sound like a narrow regulatory update, yet for people living with hereditary angioedema, prevention can shape school, work, travel and ordinary daily plans. When attacks are unpredictable, a medicine that cuts them down can mean more breathing space in everyday life.
If hereditary angioedema, or HAE, is new to you, here is the simple version. It is an inherited condition linked to a shortage of, or problem with, a protein called C1 inhibitor. The result can be episodes of swelling in different parts of the body, alongside severe stomach pain.\n\nThe reason doctors take HAE seriously is that swelling around the throat can become life-threatening if it presses on the airway. So when the MHRA approves a preventive treatment, the story is not only about medical science. It is also about reducing the risk and fear that can come with repeated attacks.
The science language in the government notice is dense, so it helps to slow it down. The MHRA says donidalorsen works by stopping the production of plasma kallikrein, which then lowers bradykinin in the bloodstream. In plain English, that means it targets part of the chain of events that can drive swelling in HAE.\n\nDawnzera is given as an injection under the skin using a pre-filled pen. For some patients, that practical detail matters almost as much as the chemistry, because how a medicine is taken can affect whether it fits into everyday life.
The main study cited by the MHRA involved 91 patients aged 12 and over with hereditary angioedema. Participants received donidalorsen every four weeks, donidalorsen every eight weeks, or a placebo, and researchers followed what happened over 24 weeks.\n\nThe results were notable. Patients given donidalorsen every four weeks had an average of about 0.4 attacks a month. Those given it every eight weeks had about 1 attack a month. The placebo group had about 2.3 attacks a month. That does not mean attacks disappeared for everyone, but it does suggest a meaningful drop compared with no active treatment.
The MHRA also says the medicine improved quality of life on a validated questionnaire looking at how symptoms affect daily life. That point is easy to rush past, but we should not. A rare condition is often measured in numbers first, yet people experience it in missed classes, cancelled plans, pain, worry and the constant question of whether an attack might start today.\n\n**What this means:** fewer attacks are important in themselves, but they can also mean more confidence in everyday routines. That is why quality-of-life data matters alongside the attack counts.
As with any medicine, approval is not the same as saying there are no risks. The MHRA's Executive Director of Healthcare Quality and Access, Julian Beach, said the decision gives patients aged 12 and over another treatment option and that the agency will continue to monitor safety and effectiveness as use becomes more widespread.\n\nAccording to the MHRA, the most common side effects, affecting more than 1 in 10 people, were reactions where the injection is given and blood tests showing liver changes. Injection-site reactions can include redness, pain, itching, bruising, swelling, skin colour changes and other irritation. That is why ongoing monitoring, follow-up appointments and clear patient information still matter after approval day.
There is also a regulatory detail worth noticing. The approval was granted to Otsuka Pharmaceutical Netherlands B.V. and the product went through the International Recognition Procedure, which is one of the MHRA's formal approval routes. The government notice says the Summary of Product Characteristics and Patient Information Leaflet will be published on the MHRA products website within seven days of approval.\n\nFor readers trying to make sense of the headline, the takeaway is this: Dawnzera is now an MHRA-approved preventive option for people aged 12 and over with hereditary angioedema, and the evidence reviewed by the regulator suggests it can reduce the number of attacks. If you are learning about HAE for the first time, that is the key point to hold on to.